International Immunopharmacology, Год журнала: 2025, Номер 159, С. 114910 - 114910
Опубликована: Май 26, 2025
Язык: Английский
Pharmacological Research, Год журнала: 2025, Номер unknown, С. 107690 - 107690
Опубликована: Март 1, 2025
Schizophrenia is a severe and debilitating psychiatric disorder that profoundly impacts cognitive, emotional, social functioning. Despite its devastating personal societal toll, current treatments often provide only partial relief, underscoring the urgent need for innovative therapeutic strategies. This review explores emerging approaches target complex neurobiological underpinnings of schizophrenia, moving beyond traditional dopamine-centric models. Among these, some novel drugs still employ multimodal mechanisms, simultaneously targeting dopaminergic serotonergic systems to enhance efficacy tolerability. Given well-documented excitatory/inhibitory imbalance in significant efforts have been directed toward addressing NMDA receptor hypofunctionality. However, strategies this pathway yet demonstrate consistent clinical efficacy. In contrast, therapies cholinergic system shown greater promise. For instance, xanomeline-trospium combination, which modulates muscarinic receptors, has recently gained approval, other molecules with similar mechanisms are currently under development. Beyond these approaches, being explored pathways, including neuroplasticity, neuroinflammation, mitochondrial dysfunction. These designed as part combinatorial strategy available antipsychotic drugs. progress, challenges remain translating experimental discoveries into effective applications. Future research should prioritize biomarker-driven precision medicine optimize individualized treatment outcomes. By integrating targets, schizophrenia may evolve more comprehensive personalized approach, disorder's full spectrum symptoms improving patient quality life.
Язык: Английский
Процитировано
2
Опубликована: Фев. 5, 2025
Control of synaptic transmission efficacy by neuronal activity and neuromodulators is pivotal for brain function. Synaptic suppression cannabinoids activating CB1 receptors has been extensively studied at the molecular cellular levels to understand basis symptoms cannabis intake. Here, we focused on another type cannabinoid receptor GPR55, which shows sensitivity cannabidiol, a chemical included in cannabis, aiming highlight its actions presynaptic Taking advantage direct patch-clamp recordings from axon terminals cerebellar Purkinje cells together with fluorescent imaging vesicular exocytosis using synapto- pHluorin, show that GPR55 suppresses as does, but through distinct modulation release machinery. Activation reduced transmitter changing neither action potential waveform nor Ca 2+ influx, making large population -responsive vesicles insensitive influx voltage-gated channels, leading substantial reduction readily releasable pool vesicles. Thus, present study identifies unique mechanism suppress atypical cannabinoid, would enable subtype-specific computation receptors.
Язык: Английский
Процитировано
0
Опубликована: Фев. 5, 2025
Control of synaptic transmission efficacy by neuronal activity and neuromodulators is pivotal for brain function. Synaptic suppression cannabinoids activating CB1 receptors has been extensively studied at the molecular cellular levels to understand basis symptoms cannabis intake. Here, we focused on another type cannabinoid receptor GPR55, which shows sensitivity cannabidiol, a chemical included in cannabis, aiming highlight its actions presynaptic Taking advantage direct patch-clamp recordings from axon terminals cerebellar Purkinje cells together with fluorescent imaging vesicular exocytosis using synapto- pHluorin, show that GPR55 suppresses as does, but through distinct modulation release machinery. Activation reduced transmitter changing neither action potential waveform nor Ca 2+ influx, making large population -responsive vesicles insensitive influx voltage-gated channels, leading substantial reduction readily releasable pool vesicles. Thus, present study identifies unique mechanism suppress atypical cannabinoid, would enable subtype-specific computation receptors.
Язык: Английский
Процитировано
0
International Immunopharmacology, Год журнала: 2025, Номер 159, С. 114910 - 114910
Опубликована: Май 26, 2025
Язык: Английский
Процитировано
0